Xeomin®: Perspectives of a novel therapeutic botulinum toxin preparation;Xeomin®: Perspektiven einer neuen therapeutischen botulinumtoxinpräparation

Aktuelle Neurologie

Volumn 33, Issue 3, 2006, Pages 138-141

  Dressler, Dirk ^a   Benecke, R ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ANTIBODY PRODUCTION; CLINICAL PRACTICE; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; REVIEW;

EID: 33646450252     PISSN: 03024350     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-915441     Document Type: Review

References (16)

1. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus 1980; 17: 21-25
2. Dressler D. Botulinum Toxin Therapy. Stuttgart, New York: Thieme Verlag, 2000
3. Dressler D, Hallett M. Immunological aspects of Botox®, Dysport®, and NeuroBloc®/Myobloc®. Eur J Neurol 2006; 13 (suppl): 11-15
4. Benecke R, Jost WH, Kanovsky P et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005; 64: 1949-1951
5. Biglan AW, Gonnering R, Lockhart LB et al. Absence of antibody production in patients treated with botulinum A toxin. Am J Ophthalmol 1986; 101: 232-235
6. Gonnering RS. Negative antibody response to long-term treatment of facial spasm with botulinum toxin. Am J Ophthalmol 1988; 105: 313-315
7. Zuber M, Sebald M, Bathien N et al. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: Frequency and significance. Neurology 1993; 43: 1715-1718
8. Dressler D, Benecke R, Bigalke H. Botulinum toxin type B (NeuroBloc®) in patients with botulinum toxin type A antibody-induced therapy failure. J Neurol 2003; 250: 967-969
9. Dressler D, Bigalke H. Antibody-induced failure of botulinum toxin type B therapy in de novo patients. Eur Neurol 2004; 52: 132-135
10. Dressier D, Dirnberger G. Botulinum toxin therapy: Risk factors for therapy failure. Mov Disord 2000; 15 (suppl 2): 51
11. Dressier D. New formulation of BOTOX®: Complete antibody-induced therapy failure in hemifacial spasm. J Neurol 2004; 251: 360
12. Dressier D, Bigalke H. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody-induced therapy failure. J Neurol 2005; 252: 904-907
13. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003; 60: 1186-1188
14. th, 2005: 64
15. Lee JC, Yokota K, Arimitsu H et al. Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology 2005; 151: 3739-3747
16. Roggenkamper P, Jost WH, Bihari K et al. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm (in press)